Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.53 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | NOS3 | P29474 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.41 |
| ▸ | MIF | P14174 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL73596 | 0.88 | CES1 (0.52) | MAOACYP2A6MAOBNOS3HPGD | |
| SCHEMBL568779 | 0.75 | TSHR (0.71) | MAOACYP2A6MAOBNOS3HPGD | |
| SCHEMBL31430380 | 0.75 | TSHR (0.71) | MAOACYP2A6MAOBNOS3HPGD | |
| SCHEMBL61808 | 0.74 | MAOA (0.44) | MAOACYP2A6MAOBCES1TSHR | |
| SCHEMBL18607288 | 0.74 | MAOA (0.91) | MAOACYP2A6MAOBNOS3HPGD | |
| SCHEMBL18716863 | 0.74 | MAOA (0.91) | MAOACYP2A6MAOBNOS3HPGD | |
| SCHEMBL4573854 | 0.74 | MAOA (0.91) | MAOACYP2A6MAOBNOS3HPGD | |
| SCHEMBL29766301 | 0.74 | MAOA (0.91) | MAOACYP2A6MAOBNOS3HPGD | |
| SCHEMBL4874556 | 0.74 | MAOA (0.91) | MAOACYP2A6MAOBNOS3HPGD | |
| SCHEMBL20445627 | 0.74 | MAOA (0.91) | MAOACYP2A6MAOBNOS3HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024149992-A1 | IMAGING COMPOUNDS FOR DETECTING OR IMAGING SENESCENT CELLS | UNIVERSITY OF DUNDEE (GB) | 2024-07-18 | — | — | WO | disclosed |
| US-12024506-B2 | Compounds | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-07-02 | — | — | US | disclosed |
| US-11969473-B2 | Multifunctional conjugates | E.P.O.S IASIS RESEARCH AND DEVELOPMENT LIMITED (CY) | 2024-04-30 | — | — | US | disclosed |
| US-11970469-B2 | Compounds useful in the treatment of disorders associated with mutant RAS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-04-30 | — | — | US | disclosed |
| US-20240108629-A1 | AZAQUINAZOLINE DERIVATIVES FOR USE IN TREATING OR PREVENTING DIROFILARIA INFECTION IN A MAMMAL | LIVERPOOL SCHOOL TROPICAL MEDICINE (GB) | 2024-04-04 | — | — | US | disclosed |
| WO-2024073383-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | PGI DRUG DISCOVERY LLC (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2024003558-A1 | PRODRUGS OF LYSYL OXIDASE INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-01-04 | — | — | WO | disclosed |
| WO-2024003557-A1 | SULFOXIMINES AS INHIBITORS OF LYSYL OXIDASE | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-01-04 | — | — | WO | disclosed |
| WO-2023233148-A1 | CANCER THERAPY | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL, (GB) | 2023-12-07 | — | — | WO | disclosed |
| EP-4277631-A1 | AZAQUINAZOLINE DERIVATIVES FOR USE IN TREATING OR PREVENTING DIROFILARIA INFECTION IN A MAMMAL | Liverpool School of Tropical Medicine (GB) | 2023-11-22 | — | — | EP | disclosed |
| US-20040198756-A1 | Medicaments | SMITHKLINE BEECHAM PLC (GB) | 2004-10-07 | — | — | US | disclosed |
| WO-2004058144-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2004-07-15 | — | — | WO | disclosed |
| EP-1419155-A2 | PIPERIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2004-05-19 | — | — | EP | disclosed |
| EP-1392686-A1 | BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES FOR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2004-03-03 | — | — | EP | disclosed |
| WO-2003064431-A2 | AMINOPIPERIDINE COMPOUNDS, PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLAXO GROUP LIMITED (GB) | 2003-08-07 | — | — | WO | disclosed |
| WO-2003010138-A2 | PIPERIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2003-02-06 | — | — | WO | disclosed |
| WO-2002096907-A1 | BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES FOR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-12-05 | — | — | WO | disclosed |
| EP-0757986-B1 | Arylpiperidine and arylpiperazine derivatives and drugs containing the same | SUNTORY LTD (JP) | 2002-06-12 | — | — | EP | disclosed |
| US-5723475-A | Arylpiperidine and arylpiperazine derivatives and medicament containing the same | SUNTORY LIMITED (JP) | 1998-03-03 | — | — | US | disclosed |
| EP-0757986-A1 | ARYLPIPERIDINE AND ARYLPIPERAZINE DERIVATIVES AND DRUGS CONTAINING THE SAME | SUNTORY LIMITED (JP) | 1997-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11969473-B2 | Multifunctional conjugates | MKI67, ACP3, CD44 | MAOA 4201/4885CYP2A6 2481/4885MAOB 3584/4885 |
| US-11970469-B2 | Compounds useful in the treatment of disorders associated with mutant RAS | KRAS, NRAS, HRAS | MAOA 4557/4885CYP2A6 2812/4885MAOB 4147/4885 |
| US-20040198756-A1 | Medicaments | PIGO, PSAP, CD68 | MAOA 2378/4885CYP2A6 3415/4885MAOB 3007/4885 |
| US-20240108629-A1 | AZAQUINAZOLINE DERIVATIVES FOR USE IN TREATING OR PREVENTING DIROFILARIA INFECTION IN A MAMMAL | AQP3, AQP1, AQP4 | MAOA 1514/4885CYP2A6 500/4885MAOB 1385/4885 |
| US-12024506-B2 | Compounds | KRAS, NRAS, HRAS | MAOA 4578/4885CYP2A6 2702/4885MAOB 4159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.